The RoleThe U.S. pharmaceutical supply chain operates on a common economic foundation: fees and reimbursement are largely calculated as a function of WAC, the manufacturer's list price. This linkage connects what distributors earn from manufacturers (the buy-side), what they charge pharmacies and health systems (the sell-side), and how those customers are reimbursed by payers (the reimbursement landscape).
This model has been remarkably durable. It is now facing a growing set of pressures: federal legislation requiring delinking of PBM compensation from list prices, FTC enforcement of net-price reimbursement standards, manufacturer WAC reductions, the slow deflation of the gross-to-net bubble, Most Favored Nation pricing, PBM reform, 340B reform, patent cliff dynamics, direct-to-consumer channels, and expanding use of cost-plus and NADAC-based constructs. Not all of these pressures will materialize at the same pace or with the same magnitude. Some represent near-term structural change; others may take years to play out or may evolve differently than current projections suggest. A core function of this role is to separate signal from noise, maintain a running view of which risks are structural versus speculative, and revise that view as the landscape moves.
What makes this particularly complex is that industry economics sit at the intersection of three interconnected systems (buy-side, sell-side and reimbursement) and no piece of it moves on its own. Most analyses of this problem look at one leg at a time. This role exists to hold all three at once and translate that integrated view into clear strategic choices.
This is a new role, created because we need a senior leader who owns both halves of this problem: what today's model is worth if these changes land, and what should replace it if they do. It is an analytical mandate and a builder mandate at once. This role will need to assess these dynamics with rigor and balance, determine which are most consequential, and design the response. It is about building the analytical foundation and strategic options that allow the company to move deliberately, and at the right time.
This role requires someone who has operated inside wholesaler economics, not observed them from the outside. The right candidate understands how a manufacturer's WAC decision flows through distribution margin, into customer contract economics, and connects to pharmacy reimbursement. They have built the models, negotiated the deals, and made commercial decisions where the margins are thin and the interdependencies are real.
Key ResponsibilitiesOwn the End-to-End Economic Framework- Build and maintain a connected view of how buy-side economics, sell-side economics, and the reimbursement landscape move together, so a shift anywhere in that chain gets traced through to its full effect rather than assessed leg by leg
- Map revenue and margin sensitivity by product category, customer segment, contract type, and channel
- Distinguish between structural shifts that require proactive model evolution and cyclical or speculative pressures that warrant monitoring but not immediate action
- Be the person executive leadership calls for a fast, credible read when a new market or regulatory development breaks
Lead the WAC-Delinking Analysis - Own the enterprise point of view on how and when WAC-linked economics may evolve across distribution, GPO, 340B, and biopharma services
- Quantify the differential impact of delinking on buy-side fees, sell-side pricing, and downstream reimbursement, recognizing that these will not move at the same pace
- Model "gap risk" scenarios where one dimension shifts faster than the others can be renegotiated
- Develop leading indicators and trigger points that signal when a scenario is materializing, rather than treating the shift as a single bet placed once
Design Alternative Models That Work Across All Three Dimensions - Originate and pressure-test alternative pricing and economic models, whether McKesson moves ahead of the market or in response to it
- Architect future-state constructs that are coherent end-to-end: the buy-side model, the sell-side model, and the reimbursement assumptions must work together
- Stress-test new models against real contract economics and actual stakeholder behavior, not just theoretical frameworks
- Identify where hybrid models will be necessary during transition, how long they need to run, and how they get managed without disrupting current profitability
Sequence the Transition Across Stakeholders - Define the specific market and regulatory signals that would tell McKesson it is time to move toward a given model
- Map the sequencing: who needs to move first among manufacturers, customers, GPOs, and other intermediaries, what gets negotiated in what order, and what the multi-year glide path looks like
- Assess the risk of moving too early (margin sacrifice, competitive disadvantage) vs. too late (forced repricing under duress)
- Coordinate with teams across the enterprise to ensure alignment between model design and deal execution
Lead External Engagement and Negotiation - Represent McKesson in sensitive, often confidential discussions with manufacturers, customers, payers, PBMs, and other channel intermediaries about how the economic relationship may need to change
- Negotiate the complex financial and commercial terms that let a new model actually get piloted with a real partner, not just modeled on a spreadsheet
- Know which terms are worth holding firm on and which ones are the price of getting a new model off the ground
- Engage with industry bodies (HDA, NACDS) on distribution and reimbursement economics
Drive Executive Alignment - Build executive briefs that take genuinely complicated economic material and turn it into a clear set of choices: what is at stake, what the options are, what is being recommended
- Work closely with Finance, Commercial, and Pricing teams across the enterprise so the buy-side view, the sell-side view, and the reimbursement read develop together instead of in separate rooms
- Collaborate with Public Policy where legislative context is needed, but own the business and economic framing
- Establish governance and decision rights for pricing model changes across segments
Qualifications Minimum Requirements - 15+ years in pricing, finance, strategy, or commercial roles within pharmaceutical distribution, wholesaling, or another part of the U.S. healthcare supply chain
- Deep, working knowledge of wholesaler and distributor economics: buy-side contracting, rebate and chargeback mechanics with manufacturers, sell-side pricing and service-fee structures with customers, and how reimbursement realities shape what customers are able to pay
- A demonstrated track record building enterprise-level economic models or pricing strategy in a complex, multi-segment environment
- A practical, firsthand understanding of the commercial realities facing manufacturers, health systems, retail and specialty pharmacy, GPOs, and payers, gained from having actually worked with or negotiated against these stakeholders
- Experience negotiating complex financial and commercial terms with external partners
- Comfortable leading work where the right answer is not yet known and the timeline is not within the company's control
- Executive communication skills strong enough to brief a C-suite on a subject most people in the room find genuinely confusing
- A track record of influencing senior executives and driving alignment across functions on high-stakes, ambiguous decisions
Preferred Requirements - Direct operating experience inside a wholesaler, distributor, or manufacturer commercial or contracting function, with hands-on exposure to both buy-side and sell-side economics
- Experience standing up a new strategic capability or team inside a large, matrixed organization
- Background in advanced analytics, financial modeling, or scenario planning for complex supply chain or distribution economics
- Existing relationships with manufacturers, health systems, retail or specialty pharmacy, GPOs, payers, or PBMs
- Working familiarity with the drug pricing policy landscape (CMS, Congress, FTC, state-level reform) is a plus, but secondary to direct commercial and economic experience across the supply chain
Critical Skills - Has a clear, well-supported point of view on how buy-side, sell-side, and reimbursement economics connect today and how that connection is likely to move over the next several years
- Has quantified McKesson's exposure across all three legs of that chain with enough rigor that Finance and the C-suite trust the numbers without re-deriving them
- A clear, balanced assessment of which external pressures are structural vs. speculative, with quantified scenario models presented to the Board and C-suite
- A transition roadmap with defined trigger points, sequencing, and no-regret moves, including a concrete plan for how hybrid economics get managed during transition
- Has designed at least one viable alternative model and gotten it into a real pilot or structured negotiation with a manufacturer, customer, or channel partner
- Is the person Finance, Commercial, and Pricing leadership all consider essential to consult before a major decision, not someone they loop in afterward
Education Bachelor's degree required. Advanced degree (MBA, MS in Finance or Economics, or similar).
Physical Requirements - Must have the ability to travel up to 50% of the time
Location Irving, TX
#LI-DNI
We are proud to offer a competitive compensation package at McKesson as part of our Total Rewards. This is determined by several factors, including performance, experience and skills, equity, regular job market evaluations, and geographical markets. The pay range shown below is aligned with McKesson's pay philosophy, and pay will always be compliant with any applicable regulations. In addition to base pay, other compensation, such as an annual bonus or long-term incentive opportunities may be offered. For more information regarding benefits at McKesson, please click here.
Our Base Pay Range for this position$231,600 - $386,000
